Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGkappa monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis[1][2].
Molecular Weight:
(146.38 kDa)
Purity:
95.00
CAS Number:
[1792181-33-9]
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted